Literature DB >> 29931401

Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.

Yoko Akune1, Masakazu Yamada2,3, Chika Shigeyasu1,4.   

Abstract

PURPOSE: To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1. STUDY
DESIGN: Cross-sectional study.
METHODS: High performance liquid chromatographic (HPLC) method reported for plasma samples was modified for tear samples. Simulated-tear solutions containing lactoferrin, lysozyme and standard solution containing 5-FU or FT were prepared for preliminary measurements. Tear samples from seven patients treated with S-1 were included. The tears were collected following S-1 administration using Schirmer's strips.
RESULTS: 5-FU and FT concentrations of pure standard solution without extraction process were detected as original concentration. However, on extraction, FT samples in simulated-tear solution showed a peak for 5-FU but not for FT. FT was converted to 5-FU in the extraction process. Decomposition from FT to 5-FU was suppressed when 50 mg/mL bovine serum albumin was added during extraction. The mean concentrations of 5-FU and FT in tears during S-1 treatment were 0.17 ± 0.11 and 1.94 ± 0.71 μg/mL, respectively.
CONCLUSION: A simple HPLC method to determine 5-FU and FT in tear samples was established.

Entities:  

Keywords:  5-fluorouracil; Cornea; High performance liquid chromatography; S-1; Tears

Mesh:

Substances:

Year:  2018        PMID: 29931401     DOI: 10.1007/s10384-018-0603-8

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  27 in total

1.  S-1 induces meibomian gland dysfunction.

Authors:  Yukihiro Matsumoto; Murat Dogru; Enrique Adan Sato; Osama M A Ibrahim; Yukako Tatematsu; Yoko Ogawa; Kazuo Tsubota
Journal:  Ophthalmology       Date:  2010-06       Impact factor: 12.079

2.  A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients.

Authors:  Yingying Miao; Ping Zhan; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1.

Authors:  Hidenaga Kobashi; Kazutaka Kamiya; Kimiya Shimizu
Journal:  Jpn J Ophthalmol       Date:  2011-03-13       Impact factor: 2.447

4.  Ocular side effects with 5-fluorouracil.

Authors:  N Christophidis; F J Vajda; I Lucas; W J Louis
Journal:  Aust N Z J Med       Date:  1979-04

5.  Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.

Authors:  Osamu Nishiyama; Hiroyuki Taniguchi; Yasuhiro Kondoh; Kazuto Takada; Kenji Baba; Hiroshi Saito; Yasuteru Sugino; Masashi Yamamoto; Toshihiko Ogasawara; Masashi Kondo; Kazuyoshi Imaizumi; Yoshinori Hasegawa; Ryujiro Suzuki; Kaoru Shimokata
Journal:  Anticancer Drugs       Date:  2011-09       Impact factor: 2.248

6.  LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.

Authors:  Barbara Büchel; Peter Rhyn; Stefan Schürch; Claudia Bühr; Ursula Amstutz; Carlo R Largiadèr
Journal:  Biomed Chromatogr       Date:  2012-03-27       Impact factor: 1.902

7.  An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield.

Authors:  Mark Adel Nassim; Farshad H Shirazi; Christine M Cripps; Shereeni Veerasinghan; Matshela J Molepo; Mihail Obrocea; Diedre Redmond; Susan Bates; Diane Fry; David J Stewart; Rakesh Goel
Journal:  Int J Mol Med       Date:  2002-10       Impact factor: 4.101

8.  Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.

Authors:  Jan H Beumer; M Boisdron-Celle; William Clarke; Jodi B Courtney; Merrill J Egorin; Erick Gamelin; Rebecca L Harney; Catherine Hammett-Stabler; Sandy Lepp; Yunying Li; Gregory D Lundell; Gwen McMillin; Gerard Milano; Salvatore J Salamone
Journal:  Ther Drug Monit       Date:  2009-12       Impact factor: 3.681

9.  Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.

Authors:  A Ohtsu; H Baba; Y Sakata; Y Mitachi; N Horikoshi; K Sugimachi; T Taguchi
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

10.  Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).

Authors:  Kiyoaki Tsukahara; Akira Kubota; Yasuhisa Hasegawa; Hideki Takemura; Tomonori Terada; Takahide Taguchi; Kunihiko Nagahara; Hiroaki Nakatani; Kunitoshi Yoshino; Yuichiro Higaki; Shigemichi Iwae; Takeshi Beppu; Yutaka Hanamure; Kichinobu Tomita; Naoyuki Kohno; Kazuyoshi Kawabata; Masanori Fukushima; Satoshi Teramukai; Masato Fujii
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.